effectFcompared to those with grade IV, which is life threatening. However, results of subgroup analyses need to be interpreted with caution as subgroup comparisons across studies are entirely observational and thus have the same limitations as any observational study.
The analysis of chronic GvHD was hampered as the analysis in individual studies was based on different populations; to analyse chronic GvHD, the statistical guidelines for EBMT recommend to restrict the population to those patients who have survived at least until day 100 post transplant as only those are considered to be at risk. However, only two studies analysed their data following this recommendation.
The pooled results for overall survival and disease-free survival show that the advantage of decreased occurrences of acute GvHD grades I-IV and II-IV does not result in an advantage concerning the survival of patients receiving corticosteroids for preventing GvHD. This might be explained by the fact that a sole reduction of low grades of acute GvHD might not increase the survival rate as (a) especially higher grades have a negative impact on survival as explained above and (b) the beneficial graft-vs-leukaemia effect might be eliminated. The latter argument should be reflected in particular in the relapse rates, as less graft-vs-leukaemia effect is supposed to enhance the relapse rates. The conclusion, which can be drawn from the analysis of disease-free survival is, however, limited: the individual studies used various terms for this outcome (eventfree survival, leukemia-free survival, and relapse-free survival) without stating the definitions used.
The occurrence of infectious complications is of special interest as (a) infections still remain an important cause of morbidity and mortality after allogeneic HSCT and (b) corticosteroids are non-specific immunosuppressive agents setting the stage more than others for infectious complications. Owing to the heterogeneity of the reported data and different outcome definitions, we could not perform a meta-analysis and thus, a final judgment about the influence of corticosteroids on the infection rate cannot be given. In addition, an interpretation is complicated by the fact that corticosteroids are used as first-line treatment for acute and chronic GvHD, which might contribute to high rates of infectionsFeven if no corticosteroids are incorporated into the prophylaxis regimen.
In conclusion, there is strong evidence that the administration of corticosteroids to the prophylaxis regimen of GvHD reduces the occurrences of acute GvHD grade I-IV and II-IV. However, there is no evidence for a survival benefit. For the occurrence of infectious complications (under the concomitant use of antibacterial, antiviral and antifungal prophylactic medication), no conclusion can be drawn due to the heterogeneity of the reported data. The subgroup analyses indicated that a 'late' administration of the steroid administration, that is, not overlapping with MTX, might have a positive influence especially on acute GvHD. Further randomized controlled trials are needed to evaluate the impact of the timing of the steroid administration and to estimate the influence of corticosteroids on chronic GvHD analysed within a homogenously defined population and on the infection rate within a homogenously treated population. Acute myeloid leukemia (AML) is intrinsically prone to resistance to conventional chemotherapeutic agents. Here, we explore the Rac family of small guanosine triphosphatases (GTPases) as novel biologic targets for AML treatment. The Rac subfamily of Rho GTPases plays an essential role in regulating normal hematopoiesis. 1 Rac proteins cycle between active GTPbound and inactive guanine diphosphate (GDP)-bound states. Of the three known Rac family members, Rac1 and Rac3 are expressed ubiquitously, whereas Rac2 is restricted to the hematopoietic system. In hematopoietic cells, Rac proteins integrate signals from growth factor, chemokine, and adhesion receptors to mediate a variety of cellular responses, including cell growth and survival, gene transcription, adhesion, motility and formation of the actin cytoskeleton. 1 We recently identified the Rac GTPases as molecular targets in BCR-ABL-induced myeloproliferative disease.
2,3 However, the role of Rac in AML has thus far not been clearly defined. Elevated levels of GTPbound Rac have been described in CD34 þ cells isolated from patients with AML. In these samples, Rac signaling was identified as a critical mediator of stem/progenitor cell and stroma interaction. 4 Recently, Wei et al. 5 observed a critical role of Rac signaling in a disease model of human CD34 þ cells transduced with the mixed lineage leukemia (MLL)-AF9 fusion oncogene. 5 Interestingly, whereas MLL-AF9 transduced cells were sensitive to Rac inhibition, cells transduced with the AML-ETO (ETO (eight twenty one)) oncogene did not depend on Rac signaling for survival and proliferation. These discrepancies Letters to the Editor prompted us to further investigate the role of Rac signaling in a panel of human AML cell lines, including the MLL generearranged ML-2 cell line and cell lines not harboring MLL rearrangements such as the histiocytic lymphoma U937 and the acute promyelocytic HL-60 cell line. We demonstrate the presence of GTP-Rac in all cell lines through p21-activated kinase-binding domain pull down and immunoblot (data not shown). Compared to purified normal human CD34 þ cells, ML-2 cells, which contain a MLL-AF6 translocation, 6 showed the most profound inhibition of cell proliferation upon pharmacologic inhibition of Rac using the small molecule Rac inhibitor NSC23766 7 ( Figure 1a) . To determine whether a correlation exists between Rac activation and the observed decrease in proliferation of ML-2 cells, we analyzed the effect of NSC23766 on GTP-Rac through the p21-activated kinasebinding domain pull-down assay and observed abrogation of Rac activation with drug treatment (Figure 1b) . We next wanted to determine whether NSC23766 treatment would impact apoptosis ( Figure 1c ) and/or cell-cycle progression of ML-2 cells (Figure 1d ). ML-2 cells displayed an increase of early and late apoptosis as measured by Annexin V/7AAD 72 h after drug exposure (Figure 1c ). In addition, Rac inhibition led to increased cell-cycle arrest in G0/G1 (Figure 1d) . Importantly, these effects were specific to ML-2 cells, as normal CD34 þ cells were not significantly affected by NSC23766 exposure. Analogous effects were observed in the MLL-AF9-containing THP-1 cell line (Supplementary Figure 1) . In contrast to these MLL gene rearranged cell lines, no significant effect of NSC23677 on cell cycle or apoptosis was observed in U937 cells and only marginal effects were observed in HL-60 cells (data not shown). To further analyze the potential therapeutic efficacy of NSC23766 in a murine xenograft model, 2 Â 10 7 ML-2 cells were transplanted into irradiated (350 Gy) non-obese diabetic/severe combined immunodeficiency (NOD/SCID) mice. Alzet osmotic pumps containing NSC23766 (two pumps, 75 mM NSC23766 per pump) or phosphate-buffered saline (PBS) were implanted on day 21 post-transplant. The pumps were exchanged for new pumps on day 35 and removed on day 49 post-transplant. Animals were monitored for survival and bone marrow chimerism of ML-2 cells (human CD45 þ ) was assessed by flow cytometry postmortem. Animals with less than 15% human CD45 þ chimerism were censored from the study (three animals in the NSC23766-and four animals in the PBS cohort). We noted a significant difference in the survival of PBS vs NSC23677-treated animals (Figure 2) . Death due to disease progression in the treatment group occurred predominantly following pump removal.
In summary, we demonstrate the impact of Rac inhibition on a panel of human AML cell lines. Whereas the drug target GTP-Rac was present in all cell lines (not shown), the MLL gene-rearranged cell line ML-2 displayed the most profound dependence on Rac signaling. This finding is consistent with recently published findings in human CD34 þ cells transduced with the MLL-AF9 oncogene and corroborated by our findings in the MLL-AF9-positive THP-1 cell line. 5 The effect of NSC23766 may point to a potential specific vulnerability of MLL rearranged leukemia to Rac inhibition. The mechanism by which the other cell lines bypass this pathway will require further studies. Taken together, our findings highlight the Rac GTPases as potential molecular targets for a subgroup of AML. Development of more potent inhibitors of Rac GTPases is warranted to enable clinical use of this approach. Despite the presence of a consistent genetic abnormality, however, CML patients display considerable clinical heterogeneity, the basis of which is poorly understood. This heterogeneity was well characterized by Sokal et al.
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2 and is reflected 24 years later by the varying responses to treatment in chronic phase patients treated with a tyrosine kinase inhibitor. 3 We therefore used a novel ultra-high-resolution genomic screening assay to search for additional acquired genomic abnormalities that might explain this clinical heterogeneity and help to assess prognosis for individual patients.
DNA was extracted from the polymorphonuclear cells in bone marrow samples from 10 previously untreated chronic phase patients. These patients subsequently received imatinib and achieved complete cytogenetic responses, at which point further polymorphonuclear-derived DNA was prepared. Comparative genomic hybridization (CGH) was performed with a 2.1 million oligonucleotide array (NimbleGen, Milton Keynes, UK; 'HD2' 070713_HG18_WG_CGH_HX1 design). The probes on this array were selected to achieve a uniform distribution throughout the genome, with approximately one probe every 1200 bp. Each DNA sample from diagnosis was competitively hybridized against the same patient's remission sample, which avoided detection of constitutional polymorphic copy number variants and limited results to acquired leukemiarelated changes. Scanned array images were imported into NimbleScan (NimbleGen) to identify copy number aberrations (CNAs) from HD2 image and intensity data. Nexus 3 software (BioDiscovery Inc., El Segundo, CA, USA) was used to visualize the normalized segmented data. For representative CNAs the CGH result was confirmed by fluorescence in situ hybridization or quantitative real-time PCR.
All 10 CML patient samples harboured detectable genomic imbalances with an average of 53 CNAs per patient (range: 4-166). Of the 530 CNAs detected 381 (72%) were amplifications and 149 (28%) were deletions. Two hundred and fifty two CNAs (48%) involved at least one known gene. Many of the CNAs that involved single genes contained the complete gene with only small quantities of adjacent non-coding DNA. The average size of CNAs was 103 kb (range 9 kb-2 Mb). Seventy different genomic regions were aberrant in two or more patients in the cohort. Of these recurrent CNAs, amplifications of the DUSP1 and PBEF1 genes were most frequently detected; they were present in four and eight patients respectively. Other genes amplified or deleted in more than one patient included DUSP22, MAPK8IP1, MAP3K11, SUPT4H1, PTPRC, GRK6 and several members of the histone gene family.
The HD2 platform provides a sensitivity that is at least an order of magnitude greater than that of those employed in previous studies. Brazma et al.
4 used a bacterial artificial chromosome array with a much lower resolution (1 Mb) and discovered 14 common cryptic abnormalities in CML blast crisis samples that were rare in chronic phase. In a comparison between Ph-positive acute lymphoblastic leukaemia and CML, Mullighan et al. 5 used a higher-resolution 250 k SNP array and observed up to 8 CNAs per patient (range 0-8) in a cohort of 23 chronic phase CML samples, but no recurrent aberrations were detected and the authors did not specify whether samples had been taken at diagnosis or later in chronic phase. Exclusive analysis of presentation samples in our study demonstrates that many CNAs are early events in CML. Furthermore, the use of the patients' remission DNA as reference material rather than pooled normal DNA confirms all observed imbalances as disease-related.
The findings of our ultra-high-resolution screening have numerous implications. The presence of multiple genomic lesions at diagnosis supports the notion of an increased level of genomic instability in CML cells and raises the possibility that one or more aberrations in addition to BCR-ABL may dictate the CML phenotype. The considerable range in the number of CNAs present at diagnosis would be consistent with a differing level of genomic instability between individual patients. Assessment of the correlation between number of CNAs detected at diagnosis and survival in an unselected group of patients might show that high-resolution genome profiling was a good method for predicting clinical outcome in CML.
The observation that many CNAs are demarcated by the extremities of individual genes, suggests that these genes might be specific targets. Furthermore, the presence of same genetic imbalances in more than one patient in the cohort suggests a role for these genes in the pathogenesis or progression of CML. The most commonly involved gene, PBEF1, has a number of functions including roles in neutrophil proliferation 6 and in the NAD anti-apoptotic pathway. 7 Expression of PBEF1 is modulated by JUN-B, 8 which is commonly downregulated in CML cells.
1 It is therefore plausible that PBEF1 could be involved in the pathogenesis of CML. DUSP1, overrepresented in 4 of our 10 patients, might be a cooperating gene as it regulates mitogen-
